Skip to main content

Table 1 Clinicopathologic factors related to bone metastases in 181 HCC patients

From: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival

   HCC Bone Metastases
Clinicopathologic Parameters No. of Cases Negative (n = 138)   PValue
(P 1, P 2
   A* (n = 113) B* (n = 25) Positive
(n = 43)
 
Age (y)      
   ≤ 60 153 94 (83.2%) 21 (84.0%) 38 (88.4%) P 1 = 0.422
   > 60 28 19 (16.8%) 4 (16.0%) 5 (11.6%) P 2 = 0.434
Gender      
   Female 25 15 (13.3%) 4 (16.0%) 6 (14.0%) P 1= 0.912
   Male 156 98 (86.7%) 21 (84.0%) 37 (86.0%) P 2 = 0.540
HBsAg      
   Negative 37 22 (19.5%) 5 (20.0%) 10 (23.3%) P 1= 0.601
   Positive 144 91 (80.5%) 20 (80.0%) 33 (76.7%) P 2 = 0.755
AFP (ng/mL) 181     
   ≤ 20 48 28 (24.8%) 7 (28.0%) 13 (30.2%) P 1= 0.544
   20 – 400 59 39 (34.5%) 9 (36.0%) 11 (25.6%) P 2 = 0.648
   ≥ 400 74 46 (40.7%) 9 (36.0%) 19 (44.2%)  
Cirrhosis      
   Absence 45 30 (26.5%) 6 (24.0%) 9 (20.9%) P 1= 0.469
   Presence 136 83 (73.5%) 19 (76.0%) 34 (79.1%) P 2 = 0.768
Satellite Lesion      
   Absence 127 94 (83.2%) 13 (52.0%) 20 (46.5%) P 1< 0.001※
   Presence 54 19 (16.8%) 12 (48.0%) 23 (53.5%) P 2 = 0.662
Tumor Size (cm) 181 6.04 ± 3.57 6.92 ± 3.34 7.26 ± 3.19 P 1= 0.051
P 2 = 0.676
Margins      
   Clear 79 56 (49.6%) 10 (40.0%) 13 (30.2%) P 1= 0.030※
   Involved 102 57 (50.4%) 15 (60.0%) 30 (69.8%) P 2 = 0.412
Vascular invasion      
   Absence 95 70 (61.9%) 9 (36.0%) 16 (37.2%) P 1= 0.006※
   Presence 86 43 (38.1%) 16 (64.0%) 27 (62.8%) P 2 = 0.921
Portal Vein Thrombosis      
   Absence 153 97 (85.8%) 20 (80.0%) 36 (83.7%) P 1= 0.739
   Presence 28 16 (14.2%) 5 (20.0%) 7 (16.3%) P 2 = 0.698
Hilar lymph nodes      
   Absence 170 109 (96.5%) 23 (92.0%) 38 (88.4%) P 1= 0.066
   Presence 11 4 (3.5%) 2 (8.0%) 5 (11.6%) P 2 = 0.488
UICC T stage      
   T1 91 74 (65.5%) 7 (28.0%) 10 (23.3%) P 1< 0.001※
   T2 38 17 (15.0%) 8 (32.0%) 13 (30.2%) P 2 = 0.856
   T3 52 22 (19.5%) 10 (40.0%) 20 (46.5%)  
Edmondson grade      
   Low (I/II) 118 81 (71.7%) 15 (60.0%) 22 (51.2%) P 1= 0.016※
   High (III/IV) 63 32 (28.3%) 10 (40.0%) 21 (48.8%) P 2 = 0.481
CXCR4      
   Negative 90 70 (61.9%) 11 (44.0%) 9 (20.9%) P 1< 0.001※
   Positive 91 43 (38.1%) 14 (56.0%) 34 (79.1%) P 2 = 0.044※
  1. * A: HCC without metastasis; B: Distal metastatic HCC without bone involvement.
  2. § P 1: Statistical analysis of HCC patients with bone metastases (n = 43) and without metastases (n = 113).
  3. P 2: Statistical analysis of distal metastatic HCC without bone involvement (n = 25) and HCC patients with bone metastases (n = 43).
  4. # Student t test.
  5. ※ Significant P value.